UK Independent Finance Intelligence · Est. 2024
Updated daily Newsletter For business
Home Hub: Insurance Travel Insurance With Arthritis UK 2026: Declaration, Cover and Finding the Right Policy
Hub: Insurance

Travel Insurance With Arthritis UK 2026: Declaration, Cover and Finding the Right Policy

CT
Chandraketu Tripathi
Finance Editor, Kaeltripton
Published 11 May 2026
Last reviewed 11 May 2026
✓ Fact-checked
Travel Insurance With Arthritis UK 2026: Declaration, Cover and Finding the Right Policy

Photo by Sasun Bughdaryan on Unsplash

Advertisement

TL;DR: Arthritis - whether osteoarthritis or rheumatoid arthritis - is a pre-existing condition that must be declared on UK travel insurance applications. Well-controlled osteoarthritis with no recent flares or surgery typically attracts modest premium loadings. Rheumatoid arthritis, particularly where managed with immunosuppressants or biological therapies, requires more careful underwriting and often specialist providers. Accurate declaration is essential: non-disclosure can invalidate a policy entirely.

KEY FACTS
  • Arthritis in all its forms is classified as a pre-existing medical condition under standard UK insurance underwriting definitions and must be declared on all travel insurance applications (abi.org.uk).
  • The Consumer Insurance (Disclosure and Representations) Act 2012 requires consumers to take reasonable care when answering insurer questions, including disclosing arthritis and all associated medication (legislation.gov.uk).
  • The FCA requires regulated travel insurers to ask clear medical screening questions and to treat consumers with pre-existing conditions fairly throughout the underwriting and claims process (fca.org.uk).
  • MoneyHelper operates a specialist travel insurance directory listing FCA-regulated providers experienced in covering musculoskeletal and autoimmune conditions, accessible at moneyhelper.org.uk.
  • UK residents travelling within the EEA can apply for a UK GHIC at nhsbsa.nhs.uk, which provides access to state healthcare at the local rate but is not a substitute for comprehensive travel insurance.

How UK Travel Insurers Assess Arthritis

The term arthritis covers a range of conditions, and the underwriting approach varies considerably depending on which type is involved. Osteoarthritis, the most common form in the UK, is a degenerative joint condition caused by cartilage breakdown over time. It is typically managed with pain relief and physiotherapy, and in some cases joint replacement surgery. For travel insurance purposes, well-controlled osteoarthritis with no recent hospitalisation, no imminent surgery, and no significant mobility restrictions generally attracts a modest assessment. The picture is different for rheumatoid arthritis, an autoimmune condition in which the immune system attacks the joints, often requiring disease-modifying antirheumatic drugs (DMARDs) or biological therapies such as adalimumab or etanercept. These treatments carry their own risk profile - including immunosuppression and infection susceptibility - which insurers factor into their underwriting. Other inflammatory arthritis types, including psoriatic arthritis and ankylosing spondylitis, are similarly assessed based on disease activity and treatment complexity. The Association of British Insurers confirms that all ongoing conditions requiring medication or medical management are classified as pre-existing conditions requiring disclosure (abi.org.uk). The FCA requires that insurers apply clear, specific screening questions and assess consumers fairly (fca.org.uk).

What to Declare When Applying for Travel Insurance With Arthritis

When completing a travel insurance medical screening questionnaire, a consumer with arthritis will typically be asked to identify the type of arthritis and the date of diagnosis. Insurers will ask about current medications including all drug names and doses, and whether the condition has required hospitalisation or surgery in the recent past. For those with osteoarthritis, questions about whether a joint replacement is planned or awaited are standard: a pending surgical procedure is a material fact that must be disclosed, as it significantly increases the risk of cancellation and of complications arising before or during travel. For those with rheumatoid arthritis or other inflammatory forms, the screening will typically ask about disease activity over the preceding months - whether there have been flares requiring steroid treatment, whether biological therapy has been started or changed recently, and whether there are any systemic complications such as cardiovascular or pulmonary involvement. The Consumer Insurance (Disclosure and Representations) Act 2012 requires consumers to answer these questions with reasonable care and accuracy: providing incomplete or inaccurate information, even unintentionally, can give an insurer grounds to reduce or reject a claim (legislation.gov.uk). MoneyHelper advises having a current medication list and GP summary available when completing any medical screening (moneyhelper.org.uk).

Cover Outcomes: What to Expect After Declaring Arthritis

After declaring arthritis, the underwriting outcome depends on the type, severity, and management of the condition. For uncomplicated osteoarthritis with no pending surgery and no recent acute episodes, most mainstream UK travel insurers will offer cover with either no exclusion or a modest premium loading. A specific exclusion applied to arthritis-related claims is possible but not universal for mild presentations. For rheumatoid arthritis managed with DMARDs or biological therapies, the assessment is more complex. Some insurers will cover the condition in full; others will apply an exclusion for claims arising from arthritis or related autoimmune complications; and a minority may decline to offer cover entirely for complex, recently active profiles. Where a joint replacement surgery is pending, the probability of a cancellation claim before travel significantly increases, and this is likely to be reflected in either a higher premium or an exclusion for cancellation related to the arthritis or planned procedure. Consumers should check the policy wording carefully for the scope of any exclusion: some policies exclude claims relating to "any musculoskeletal condition" rather than arthritis specifically, which is considerably broader. The ABI notes that consumers unable to find suitable cover should be directed to specialist providers (abi.org.uk).

Finding Specialist Travel Insurance for Arthritis in the UK

For those with complex arthritis profiles - including recently active rheumatoid arthritis, biological therapy, or pending joint surgery - specialist medical travel insurers are likely to offer more appropriate and reliable cover than mainstream comparison site options. These providers apply more granular underwriting criteria and are experienced in assessing autoimmune and musculoskeletal conditions. The MoneyHelper travel insurance directory at moneyhelper.org.uk/en/everyday-money/insurance/travel-insurance-directory is the FCA-endorsed starting point for consumers who have been declined or quoted with unacceptable exclusions by mainstream providers. The FCA requires any regulated insurer unable to offer a suitable policy to direct consumers to this resource (fca.org.uk). When approaching a specialist provider, applicants should be prepared to describe their condition in detail, including current disease activity, all medications, and any surgical history. Those managing rheumatoid arthritis with biological therapy should confirm whether the policy covers emergency administration or complications related to that treatment while abroad, as this is not always included as standard. Annual multi-trip policies from specialist providers may offer value for those who travel regularly.

Travelling Abroad With Arthritis: Practical Considerations

Practical preparation before travel can significantly reduce risk and improve the travel experience for those with arthritis. The FCDO publishes country-specific travel advice at gov.uk/foreign-travel-advice, including information on local healthcare standards and accessibility, which is relevant for those with mobility limitations. Travellers to EEA countries should apply for a UK GHIC at nhsbsa.nhs.uk before departure: this provides access to state healthcare at the local rate but does not cover all costs, repatriation, or private medical care, and therefore does not replace travel insurance. Medication continuity is important: carry sufficient supply for the full trip plus additional days, and carry medications in hand luggage. For those on biological therapies requiring refrigeration or specialist administration, advance planning with the clinical team and the insurer's medical assistance team is advisable before travel. A GP or consultant summary letter confirming the diagnosis, treatment, and emergency contacts can help overseas medical staff provide appropriate care promptly. Those with significant mobility limitations should consider whether their destination's infrastructure - airports, hotels, tourist sites - can accommodate their needs, and should notify airlines and accommodation providers in advance of any requirements. In the event of any arthritis-related health issue abroad, contacting the insurer's 24-hour emergency line promptly is essential for protecting the claim.

Editorial Disclaimer: Kaeltripton.com is an independent editorial publisher and is not authorised or regulated by the Financial Conduct Authority. Content is for informational purposes only and does not constitute financial, investment, tax, legal or regulatory advice. Always verify rates and product details with the relevant provider, the FCA register, HMRC or the Bank of England before any financial decision.

Frequently Asked Questions

Do I need to declare arthritis if it is well controlled and only causes occasional discomfort?

Yes. The Consumer Insurance (Disclosure and Representations) Act 2012 requires consumers to answer insurer screening questions accurately. If an insurer asks about musculoskeletal conditions, joint conditions, or ongoing medication, arthritis must be declared regardless of how mild or well-controlled it is. Failure to disclose can invalidate a claim (legislation.gov.uk).

Does rheumatoid arthritis always result in a higher travel insurance premium than osteoarthritis?

Not automatically, but it is common. Rheumatoid arthritis is an autoimmune condition often requiring immunosuppressant or biological therapy, which represents a more complex underwriting risk than uncomplicated osteoarthritis. The premium impact depends on current disease activity, treatment type, and the presence of any related systemic conditions. Each application is assessed individually.

I am waiting for a hip replacement - does this affect my travel insurance?

Yes, significantly. A pending surgical procedure is a material fact that must be disclosed. It increases the risk of a cancellation claim if surgery is brought forward, and may affect cover for any arthritis-related complications before the operation. Some insurers will exclude cancellation claims related to the pending procedure, while others may decline to cover the relevant period. Disclosing this clearly at the time of application is essential.

Can I use a GHIC instead of travel insurance if I have arthritis?

No. A UK GHIC provides access to state healthcare in EEA countries at the local rate, but it does not cover all treatment costs, does not cover repatriation to the UK, and is not a substitute for travel insurance. NHS Business Services Authority confirms this explicitly at nhsbsa.nhs.uk. Comprehensive travel insurance that includes the arthritis condition is required alongside the GHIC for adequate protection.

Where can I find a specialist insurer if mainstream providers have declined my application?

The MoneyHelper travel insurance directory at moneyhelper.org.uk lists FCA-regulated specialist providers experienced in covering pre-existing conditions including arthritis. Under FCA rules, regulated insurers that cannot offer a suitable policy must direct consumers to this directory. If a claim is subsequently disputed, the Financial Ombudsman Service at financial-ombudsman.org.uk can independently review the case (fca.org.uk).

How We Verified This Guide

This guide was researched against primary UK regulatory sources including the Association of British Insurers (abi.org.uk), the Financial Conduct Authority (fca.org.uk), MoneyHelper (moneyhelper.org.uk), legislation.gov.uk, NHS Business Services Authority (nhsbsa.nhs.uk), the Financial Ombudsman Service (financial-ombudsman.org.uk), and FCDO foreign travel advice at gov.uk. Last reviewed May 2026 by Chandraketu Tripathi, finance editor at Kaeltripton.

Sources

Advertisement

Editorial Disclaimer

The content on Kaeltripton.com is for informational and educational purposes only and does not constitute financial, investment, tax, legal or regulatory advice. Kaeltripton.com is not authorised or regulated by the Financial Conduct Authority (FCA) and is not a financial adviser, mortgage broker, insurance intermediary or investment firm. Nothing on this site should be construed as a personal recommendation. Rates, figures and product details are indicative only, subject to change without notice, and should always be verified directly with the relevant provider, HMRC, the FCA register, the Bank of England, Ofgem or other appropriate authority before any financial decision is made. Past performance is not a reliable indicator of future results. If you require regulated financial advice, please consult a qualified adviser authorised by the FCA.

CT
Chandraketu Tripathi
Finance Editor · Kaeltripton.com
Chandraketu (CK) Tripathi, founder and lead editor of Kael Tripton. 22 years in finance and marketing across 23 markets. Writes on UK personal finance, tax, mortgages, insurance, energy, and investing. Sources: HMRC, FCA, Ofgem, BoE, ONS.

Stay ahead of your money

Free UK finance guides, rate changes and money-saving tips — straight to your inbox. No spam, unsubscribe anytime.

Read More

Get Kael Tripton in your Google feed

⭐ Add as Preferred Source on Google